Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.20.1
Basis of Presentation and Significant Accounting Policies (Details)
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Noncontrolling Interest [Line Items]            
Accumulated deficit $ 110,889,854   $ 104,597,748      
Net loss 6,373,420 $ 5,819,081        
Cash, cash equivalents and short term investments 26,400,000          
Net loss: Non-controlling interest (81,314) $ (103,605)        
Derivative warrant liability $ 41,360          
Number of Operating Segments | segment 1          
Heat I            
Noncontrolling Interest [Line Items]            
Ownership interest in subsidiary 100.00%          
Pelican Therapeutics, Inc.            
Noncontrolling Interest [Line Items]            
Ownership interest in subsidiary 85.00%          
Pelican Therapeutics, Inc.            
Noncontrolling Interest [Line Items]            
Percentage of voting interests acquired in acquisition       85.00% 80.00% 80.00%